Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim report Q2/2022: Improved sales give confidence for the future

Significant Significant events after the quarterevents inQ2 · In · To secure long-time financing of the operations, the Board ofJune, Directors decided in July to raise about SEK 74.7 million throughEnzymatica a rights issue. The new issue is 100% guaranteed by subscriptionAB signed a commitments together with underwriting agreements from theloan company’s three largest shareholders, as well as the company’sagreement Chairman of the Board and CEO.with thethreelargestowners, aswell as thecompany’sCEO andchairman ofthe board,

Prevas interim report January – June 2022

Solid quarter with increased profitability. April-June 2022 · Net turnover 335.3 MSEK (313.2) · Operating profit/loss EBITA 34.9 MSEK (29.8) · Operating margin EBITA 10.4% (9.5) · Operating profit/loss EBIT 33.6 MSEK (28.9) · Operating margin EBIT 10.0% (9.2) · Profit after tax 28.7 MSEK (1.,5) · Profit per share before dilution 2.16 SEK (1.35) January-June 2022 · Net turnover 650.8 MSEK (614.1) · Operating profit/loss EBITA 79.1 MSEK (61.3) · Operating margin EBITA 12.2% (10.0) · Operating profit/loss EBIT 76.9 MSEK (59.6) · Operating

Obducat receives order valued at 16 million SEK from a customer in Europe

OBDUCAT AB (pub) subsidiary Obducat Europe GmbH, a leading supplier of system solutions for lithography processing, has received an order from a customer in Europe, for the supply of a fully automated and highly customized Wet Processing Tool. The order value amounts to approx. 16 million SEK. The order value will be included in the second quarter's order intake 2022. The tool will be installed in an existing semiconductor fab facility and will be used in a combined wet process- and wafer test application. Further information cannot be disclosed at this point in time. The tool will be

Interim Report 1 April – 30 June 2022

In summing up, we can declare a strong second quarter whose performance is one of the Group's most profitable for the April-June period ever. Operating profit came in at SEK 20 million, which is a great improvement and a clear indication that we are on the right track towards restoring profitability. Even when we exclude the support we received as a result of the restrictions, the Group's performance shows clear improvements in profitability. In this context, we note that the Covid-related restrictions from previous periods, combined with the unrest in the world at large, had a negative

Enhertu approved in EU for HER2-positive mBC

19 July 2022 07:00 BST Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens Approval broadens indication for AstraZeneca and Daiichi Sankyo's Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1) AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European

Enhertu approved in the EU for patients with HER2-positive metastatic breast cancer treated with one or more prior anti-HER2-based regimens

Approval broadens indication for AstraZeneca and Daiichi Sankyo’s Enhertu across Europe to earlier use in HER2-positive metastatic breast cancer. Based on ground-breaking DESTINY-Breast03 results in which Enhertu demonstrated a 72% reduction in the risk of disease progression or death vs. trastuzumab emtansine (T-DM1).AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based

Juuso Pajunen appointed as CFO of Terveystalo

Terveystalo Plc. Stock Exchange Release 19.7.2022 at 09:01 EEST Juuso Pajunen, b. 1981, M.Sc. (Econ.) has been appointed as Chief Financial Officer and member of the Executive team. Juuso Pajunen will start in the position in January 2023 the latest. Pajunen joins Terveystalo from AFRY, an engineering and consulting company, where he currently holds the position of CFO. Prior to his current position, Pajunen held multiple senior financial positions at Pöyry Group, including CFO and the Head of Group Business Control.  “I’m delighted to announce appointment of Juuso Pajunen as our

Embellence Group Interim Report Q2 2022

Navigating towards our long-term goalSecond quarter 2022 · Net sales amounted to MSEK 189.9 (160.0), up 18.7%. · Negative organic growth of -4.0%. · Adjusted EBITA* amounted to MSEK 24.4 (22.9), up 6.6%. · EBITA amounted to MSEK 22.0 (21.2), up 3.8%. · Net profit for the period** amounted to MSEK 2.0 (13.3), and earnings per share for the period before dilution were SEK 0.09 (0.62). · Operating cash flow amounted to MSEK 26.5 (17.8). *EBITA excluding acquisition costs related to the acquisition of Artscape, as well as restructuring costs in the Nordics.**Net profit

Getinge Interim Report January-June 2022: Recovery in elective surgery overshadowed by external challenges

“Order intake and net sales declined organically by 5% and 7.5% respectively in the quarter, which however ended with increased order intake,” says Mattias Perjos, President & CEO. ”Our customers are planning for a normal flu season in the second half of the year, which is expected to result in a recovery in ICU products”.The performance for the quarter as a whole was impacted by reduced production of COVID-19 vaccines and the number of patients requiring life support in Intensive Care Units (ICUs) declining significantly more than both the health care sector and Getinge had predicted,

Interim report 1 January – 30 June 2022

Halmstad, 19 July 2022SECOND QUARTER (1 April – 30 June 2022) · Net sales for the quarter amounted to MSEK 53 (36). · Operating profit before depreciation and amortisation (EBITDA) totalled MSEK 25 (12). · Operating profit (EBIT) was MSEK 10 (-6). · Profit/loss before tax, before items affecting comparability, was MSEK 7 (-10) and after items affecting comparability MSEK -6 (-6). · Profit/loss after tax totalled MSEK -6 (-6), corresponding to SEK -0.13 (-0.16) per share. · Operating cash flow was MSEK 67 (12) and was impacted by an increase in current liabilities related

Alimak Group: Interim report January – June 2022

Strong order intake and profitable growth · Strong order intake driven by Facade Access, Construction and Industrial · Group revenue increased by 13% and by 2% organically · Group EBITA increased by 12% · Initiatives to accelerate growth continue to gain tractionSecond quarter 2022 –        Order intake increased by 37% to MSEK 1,249 (915) with an organic increase of 24% –        Strong growth in order intake in Facade Access of 78%, Construction of 27% and in Industrial of 35% –        Equipment orders in the Group increased 56% with an organic increase of 44% –

Notice to the Extraordinary General Meeting of Basware Corporation

Basware Corporation, stock exchange release, 19 July 2022 at 9:00 a.m. EESTNotice is given to the shareholders of Basware Corporation (“Basware” or the “company”) to the Extraordinary General Meeting to be held on Tuesday, 9 August 2022 at 9:00 a.m. EEST in the company’s headquarters, at the address of Linnoitustie 2 B, Espoo, Finland in Cello-building. The reception of persons who have registered for the meeting will commence at 8:30 a.m. EEST. On 14 April 2022, Sapphire BidCo Ltd (the “Offeror”) and Basware entered into a combination agreement (the “Combination Agreement”) pursuant to

Viaplay commissions real-life drama ‘Roombeek’ as next Dutch Original

· ‘Roombeek’ based on Enschede fireworks warehouse explosion in May 2000 · Four-part series produced by EndemolShine Scripted, a Banijay Benelux label · Viaplay set to premiere at least 70 Originals in 2022 One of the biggest disasters in recent Dutch history, the Enschede fireworks warehouse explosion in May 2000, will become the subject of a four-part scripted Viaplay Original series. The compelling drama ‘Roombeek’ will relate the devasting human impact of the tragedy and its aftermath, and is produced by EndemolShine Scripted, a Banijay Benelux label. ‘Roombeek’ is the latest

Hansa Biopharma half year report 2022

•    Continued solid sales in Q2•    Positive NICE recommendation obtained •    Completed enrollment in imlifidase Phase 2 program in AMR •    Peter Nicklin elected as new Chairman of the Board of DirectorsLund, Sweden July 19, 2022, Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and interim report for January to June 2022. Highlights for the second quarter 2022 · Continued solid sales in the second quarter with SEK 19.5m in product sales; total revenue amounted to SEK 26.4m. · On June

Terveystalo Group Half-Year Report January-June 2022: Strong growth continued, margin pressure due to changes in operating environment

Terveystalo Plc, Half-Year Report 19 July, 2022 at 09:00 EEST   This release is a summary of Terveystalo's Half-Year Report 2022. The full release is attached to this stock exchange release and is available on our website at: https://www.terveystalo.com/en/company/investors/reports-and-presentations/   April-June 2022 in brief •          Revenue increased by 15.6% year-on-year to EUR 318.2 (275.3) million. The external revenue of the Sweden and others segment1) came to EUR 25.2 million representing 9.2%-points of the revenue growth. •          Adjusted2) earnings before

Sobi publishes Q2 2022 report

Swedish Orphan Biovitrum AB (publ)  (Sobi®) today announced its report for the second quarter of 2022   April – June 2022 · Total revenue SEK 3,876 M (3,211), +21 per cent, +10 per cent at constant exchange rates (CER)1 · Haematology revenue SEK 2,688 M (2,125), +16 per cent at CER of which Elocta® SEK 1,107 M (1,005), +6 per cent at CER; Alprolix® SEK 468 M (438), +2 per cent at CER; Doptelet® SEK 618 M (230), +126 per cent at CER and Aspaveli®/Empaveli™ SEK 38 M (-) · Immunology revenue SEK 847 M (752), stable at CER of which Kineret® SEK 545 M (550),

Semcon Interim Report January-June 2022

Continued high demand and profitability.Second quarter · Net sales of SEK 500 million (445), up 12.4%  · The adjusted operating profit, excluding non-recurring costs related to the separation project, amounted to SEK 43 million (40), yielding an operating margin of 8.5% (8.9) · The operating profit amounted to SEK 35 million (40), yielding an operating margin of 7.1% (8.9) · Profit after tax amounted to SEK 28 million (30)  · Earnings per share (EPS) after dilution amounted to SEK 1.58 (1.69) January-June · Net sales of SEK 995 million (864), up 15.2%  · The

Enzymatica’s Board of Directors decides on a new rights issue of SEK 74.7 million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.The Board of Directors of Enzymatica AB (publ) (“Enzymatica” or the “Company”) has decided to carry out a rights issue amounting to SEK 74.7 million, with preferential rights for existing shareholders, by exercising the authorization of a new rights issue from the Annual General Meeting 2022 (the “Rights issue”). The purpose of the Rights issue is to secure the

Finnair Group Half-year Report 1 January – 30 June 2022

Finnair Plc             Half-year Report            19 July 2022 at 9.00 a.m. EEST Demand for travel started to normalise in many markets; closed Russian airspace and record high fuel price burden Finnair’s profitability April – June 2022                                           · Earnings per share were -0.20 euros (-0.09)*. · Revenue increased by 392.0% to 550.3 million euros (111.8). · Comparable operating result was -84.2 million euros (-151.3). Operating result was -92.9 million euros (-139.1). · Record high fuel price had an adverse cost impact of c. 126 million

Quarterly Report Q2 2022

Strong growth and profit in turbulent times Second quarter · Net sales increased by 25% to SEK 29,466 M (23,648), with organic growth of 13% (23) and acquired net growth of 0% (5). · Very strong organic growth in Americas and Entrance Systems and strong growth in EMEIA and Global Technologies, but organic sales declined in Asia Pacific. · Three acquisitions with combined annual sales of about SEK 1,100 M were signed in the quarter. · Operating income (EBIT) increased by 23% and amounted to SEK 4,406 M (3,589), corresponding to an operating margin of 15.0% (15.2). · Net

Svenska Aerogel expands its distributor network into the UK & Ireland with the appointment of coatings specialist Stort Chemicals Ltd.

Stort Chemicals has been appointed as Svenska Aerogel’s new distributor in England and Ireland. With 40 years of experience, Stort is a strong market player with coatings being their main focus. Together with Stort, Svenska Aerogel will be able to reach a new geographical area in which the company sees great potential.Family-owned Stort Chemicals, headquartered in Bishop’s Stortford, distributes products for several well-known European raw material manufacturers. They have multiple local warehouses and valuable experience of importing to England, which has become a challenge for many

Change in Oriola Management Team

Oriola Corporation Stock Exchange Release 19 July 2022 at 9.00 a.m. Change in Oriola Management Team Timo Leinonen, M. Sc. (Admin), has been appointed Oriola Corporation’s Chief Financial Officer (CFO) and member of the Oriola Management Team. He will report to Katarina Gabrielson, CEO of Oriola. Leinonen is currently working as CFO at StaffPoint, where he has been working since 2018. Prior to that, Leinonen has also been CFO at Lassila & Tikanoja Plc., Ixonos Plc. and Terveystalo Plc. ”Oriola is in the middle of the important turnaround and transformation phase and I believe Timo

Lagercrantz Interim Report 2022/23 Q1

First quarter (1 April – 30 June 2022) · Net revenue increased by 23% to MSEK 1,597 (1,301). · Organically, net revenue increased by 9%. · Operating profit (EBITA) increased by 25% to MSEK 265 (212), equivalent to anoperating margin of 16.6% (16.3). ·  Profit after financial items (EBT) increased by 29% to MSEK 232 (180). · Profit after taxes increased by 29% to MSEK 179 (139). Earnings per shareafter dilution for the latest 12-month period amounted to SEK 3.00 (SEK 2.80 forthe financial year 2021/22). · Return on equity for the latest 12-month period amounted

Changes in Group Executive Management

Juuso Pajunen, CFO at AFRY, has decided to leave the companyJuuso Pajunen will leave his position as CFO and member of the Group Executive Management at AFRY for a new position outside the company. "It has been a pleasure to work with Juuso Pajunen and during the recent years he has made a substantial contribution to the development of AFRY, including the integration of ÅF and Pöyry in 2019. I would like to thank Juuso for his invaluable commitment, leadership and collaboration, and wish him all the best with his future plans.” said Jonas Gustavsson. “I’ve had the privilege to be part

There are no items matching the current filter
There are no more items matching the current filter
Back to top